C4 Therapeutics (CCCC) News Today $3.94 +0.08 (+2.07%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $10.67January 17 at 2:15 AM | americanbankingnews.comC4 Therapeutics announces anticipated 2025 milestonesJanuary 14, 2025 | markets.businessinsider.comC4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in OncologyJanuary 14, 2025 | markets.businessinsider.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buyJanuary 14, 2025 | marketbeat.comAnalysts Issue Forecasts for C4 Therapeutics FY2029 EarningsJanuary 10, 2025 | americanbankingnews.comC4 Therapeutics price target raised to $50 from $39 at BrooklineJanuary 8, 2025 | markets.businessinsider.comC4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | markets.businessinsider.comEquities Analysts Issue Forecasts for C4 Therapeutics FY2029 EarningsC4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Brookline Capital Management issued their FY2029 earnings estimates for shares of C4 Therapeutics in a report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will earn $28.08 per share for tJanuary 8, 2025 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 11.0% in DecemberC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 8,870,000 shares, an increase of 11.0% from the November 30th total of 7,990,000 shares. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is presently 7.3 days.January 1, 2025 | marketbeat.comWhy C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.comState Street Corp Cuts Position in C4 Therapeutics, Inc. (NASDAQ:CCCC)State Street Corp lowered its holdings in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 6.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,806,913 shares of the company's stock afteDecember 25, 2024 | marketbeat.comWells Fargo Upgrades C4 Therapeutics (CCCC)December 20, 2024 | msn.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have earned an average rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the coDecember 20, 2024 | marketbeat.comC4 Therapeutics upgraded to Overweight from Equal Weight at Wells FargoDecember 19, 2024 | markets.businessinsider.comC4 Therapeutics (NASDAQ:CCCC) Upgraded to "Overweight" at Wells Fargo & CompanyWells Fargo & Company upgraded shares of C4 Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $8.00 to $12.00 in a research report on Thursday.December 19, 2024 | marketbeat.comFmr LLC Raises Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)Fmr LLC increased its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 687.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 185,941 shares of the company's stock after acquirinDecember 17, 2024 | marketbeat.comC4 TherapeuticsDecember 13, 2024 | forbes.comC4 Therapeutics (CCCC) Gets a Hold from Morgan StanleyDecember 10, 2024 | markets.businessinsider.comPoint72 Asset Management L.P. Boosts Stock Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)Point72 Asset Management L.P. grew its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 331.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,201,848 shares of the company's stock after buying an additioDecember 9, 2024 | marketbeat.comC4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 DegraderDecember 8, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Bought by Wasatch Advisors LPWasatch Advisors LP grew its holdings in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 17.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,677,368 shares of the company's stock after purchasing an additional 830,218 shares durDecember 1, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Hold" from AnalystsC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has been given an average recommendation of "Hold" by the six analysts that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommeNovember 25, 2024 | marketbeat.comC4 Therapeutics appoints Hoerter to board of directorsNovember 22, 2024 | markets.businessinsider.comC4 Therapeutics Appoints Steve Hoerter to BoardNovember 21, 2024 | markets.businessinsider.comC4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of DirectorsNovember 20, 2024 | globenewswire.comStephens & Co. Initiates Coverage of C4 Therapeutics (CCCC) with Equal-Weight RecommendationNovember 19, 2024 | msn.comC4 Therapeutics initiated with an Equal Weight at StephensNovember 18, 2024 | markets.businessinsider.comC4 Therapeutics (NASDAQ:CCCC) Now Covered by Analysts at StephensStephens assumed coverage on shares of C4 Therapeutics in a research note on Monday. They set an "equal weight" rating and a $4.00 price objective for the company.November 18, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short InterestC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 5,850,000 shares, a decrease of 12.0% from the October 15th total of 6,650,000 shares. Based on an average trading volume of 975,000 shares, the days-to-cover ratio is currently 6.0 days.November 16, 2024 | marketbeat.comC4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical TrialNovember 7, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for C4 Therapeutics (CCCC)November 7, 2024 | markets.businessinsider.comMorgan Stanley Keeps Their Hold Rating on C4 Therapeutics (CCCC)November 5, 2024 | markets.businessinsider.comC4 Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 2, 2024 | finance.yahoo.comC4 Therapeutics Advances in Protein Degradation TherapyNovember 1, 2024 | markets.businessinsider.comC4 Therapeutics files $400M mixed securities shelfOctober 31, 2024 | markets.businessinsider.comC4 Therapeutics files to sell 4.87M shares of common stock for holdersOctober 31, 2024 | markets.businessinsider.comC4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsOctober 31, 2024 | markets.businessinsider.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Moderate Buy" by BrokeragesC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a buOctober 31, 2024 | marketbeat.comWe're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash WiselyOctober 29, 2024 | finance.yahoo.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 28, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest UpdateC4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 6,650,000 shares, a decline of 39.6% from the September 30th total of 11,010,000 shares. Based on an average trading volume of 988,500 shares, the days-to-cover ratio is currently 6.7 days.October 26, 2024 | marketbeat.comC4 Therapeutics, Inc.: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.October 17, 2024 | finanznachrichten.deC4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.October 15, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Sold by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC lowered its position in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 26.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 560,959 shares of the company's stockOctober 12, 2024 | marketbeat.comC4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity SummitOctober 9, 2024 | globenewswire.comRenaissance Technologies LLC Sells 170,600 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)Renaissance Technologies LLC cut its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 42.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 235,200 shares of the company's stock afterOctober 7, 2024 | marketbeat.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Hold" from BrokeragesShares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have been given a consensus recommendation of "Hold" by the seven brokerages that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold rating and three have issued a buy rating on the comOctober 6, 2024 | marketbeat.comPoint72 Asset Management L.P. Sells 627,892 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)Point72 Asset Management L.P. reduced its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 69.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 278,580 shares of the company's stock after seOctober 4, 2024 | marketbeat.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 30, 2024 | globenewswire.comC4 Therapeutics, Inc. (NASDAQ:CCCC) is Lynx1 Capital Management LP's 4th Largest PositionLynx1 Capital Management LP lifted its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 89.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,880,527 shares of the company's stock after buying anSeptember 27, 2024 | marketbeat.com Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address CCCC Media Mentions By Week CCCC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CCCC News Sentiment▼0.030.41▲Average Medical News Sentiment CCCC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CCCC Articles This Week▼42▲CCCC Articles Average Week Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rocket Pharmaceuticals News Today Zymeworks News Today Adaptive Biotechnologies News Today Gyre Therapeutics News Today Poseida Therapeutics News Today Oculis News Today Nuvation Bio News Today Anavex Life Sciences News Today AbCellera Biologics News Today CureVac News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CCCC) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CCCC Stock Alerts